Overview

Muscadine Plus (MPX) In Men With Prostate Cancer

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This research is being done to determine if men with rising PSA after initial therapy for localized prostate cancer who display the Alanine/Alanine SOD2 genotype of MnSOD and supplement their diet with MPX have greater decrease in PSA slope following treatment compared to men that do not supplement with MPX.
Phase:
Phase 3
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborator:
Greater Washington Community Foundation